Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd

Contributed by: PR Newswire

Tags

MÖLNLYCKE-MediWound

More Like This

Mölnlycke® Health Care and Transdiagen announce research collaboration to drive innovation in wound care

Mölnlycke and Ondine join forces against HAIs

PR Newswire associated0

MolecuLight Secures $27.5 Million From Hayfin, a Leading Healthcare Institutional Investor

PR Newswire associated0

MolecuLight Secures $11.7 Million in Financing to Accelerate Global Expansion

Mölnlycke® Health Care acquires P.G.F. Industry Solutions GmbH, the manufacturer of Granudacyn®, a range of solutions for wound cleansing and moisturising

DEBx Medical Secures Expanded Investment from TVM Capital Healthcare

PR Newswire associated0

MolecuLight® Imaging Significantly Improves Outcomes and Cuts Costs for Deep Sternal Wound Infections in Taiwan Study; Signals Expansion into Surgical Applications

PR Newswire associated0

First Breakthrough Study Highlights Superiority of MatriDerm® in Wound Healing